Standout Papers

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial 2024 202653
  1. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial (2024)
    Kang Wang, Yan‐Jun Xiang et al. Nature Medicine

Immediate Impact

49 standout
Sub-graph 1 of 23

Citing Papers

Liver diseases: epidemiology, causes, trends and predictions
2025 Standout
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
2 intermediate papers

Works of Chong‐De Lu being referenced

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancy
2019
and 1 more

Author Peers

Author Last Decade Papers Cites
Chong‐De Lu 144 115 74 141 129 16 359
K Umeshita 116 107 78 85 87 17 353
Zhao Yin-nong 85 98 76 111 154 24 401
Nicolai Aagaard Schultz 77 79 67 146 118 20 313
Ting‐Jung Wu 162 110 110 62 81 21 349
Wentao Wang 161 77 85 72 70 21 312
Yanfu Sun 144 149 79 61 87 15 360
Moon Soo Koh 166 97 99 67 125 22 387
Xiu-Xian Ma 121 147 81 54 182 25 403
Hesham M. Hassabo 188 67 64 112 171 17 391
Luca Ielasi 223 96 71 81 64 23 353

All Works

Loading papers...

Rankless by CCL
2026